Comparative Efficacy and Safety of Potassium-Competitive Acid Blocker- and Proton Pump Inhibitor-Based Bismuth Quadruple Therapy for <i>Helicobacter pylori</i> Eradication: A Network Meta-Analysis.

ABSTRACT:

Background and aims

The eradication of Helicobacter pylori (H. pylori) reduces the incidence of gastric cancer. However, the efficacy of the widely used triple therapy for eradicating H. pylori has progressively reduced. This may have resulted from the increase in clarithromycin resistance in recent years. Recent guidelines recommend the use of bismuth quadruple therapy (BQT) as first-line eradication therapy for H. pylori infection in areas with high (>15%) or unknown clarithromycin resistance. However, the eradication rates of proton pump inhibitor (PPI)-based BQT remain below the required standard. This systematic review aimed to evaluate the use of novel acid suppressant (potassium-competitive acid blocker [P-CAB])-based BQT compared with PPI-based BQT for

SUBMITTER: Taufiqqurrachman I 

PROVIDER: S-EPMC12320159 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature